The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer
dc.contributor.author | Ilgun, A.S. | |
dc.contributor.author | Aktepe, F. | |
dc.contributor.author | Gonullu, O. | |
dc.contributor.author | Kapucuoglu, N. | |
dc.contributor.author | Yararbas, K. | |
dc.contributor.author | Alco, G. | |
dc.contributor.author | Ozmen, V. | |
dc.date.accessioned | 2022-11-04T19:55:47Z | |
dc.date.available | 2022-11-04T19:55:47Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1744-8301 | |
dc.identifier.uri | https://doi.org/10.2217/fon-2022-0157 | |
dc.identifier.uri | http://hdl.handle.net/11446/4629 | |
dc.description.abstract | Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: 115 patients with pre-NAC core biopsies and post-NAC surgical resection specimens were reviewed. Results: There was no significant change between pre- and post-treatment sTILs. Both pre- and post-NAC sTILs were significantly lower in patients with luminal A subtype. An increase in sTILs was observed in 21 (25.9%) patients after NAC, a decrease in 29 (35.8%) and no change in 31 (38.3%; p = 0.07). Pretreatment sTIL density was independent predictor of pathological complete response in multivariate analyses (odds ratio: 1.025, 95% CI: 1.003-1.047; p = 0.023). Conclusion: High sTIL density in core biopsies was independently related to pathological complete response. In addition, ER appears to be the most crucial factor determining the rate of sTIL.New studies have shown that the tumor microenvironment is critical in tumor behavior. Immune cells surrounding tumor cells are the main components of the tumor microenvironment. Our study aimed to investigate the change in immune cells before and after chemotherapy in breast cancer patients. Our study included 115 patients. All patients underwent chemotherapy before surgery to shrink the tumor. Tru-cut biopsy pieces and the breast tissue obtained after surgery were examined. The presence of estrogen or progesterone receptors on tumor cells decreased the number of immune cells surrounding the tumor cells. The number of immune cells did not decrease after chemotherapy. Another finding was that the greater the number of immune cells around the tumor, the more likely that the tumor would disappear after chemotherapy. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | NLM (Medline) | en_US |
dc.relation.ispartof | Future oncology (London, England) | en_US |
dc.identifier.doi | 10.2217/fon-2022-0157 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | breast cancer | en_US |
dc.subject | immune markers | en_US |
dc.subject | immunogenicity | en_US |
dc.subject | lymphocytic infiltrate, immune-cell infiltration | en_US |
dc.subject | neoadjuvant treatment | en_US |
dc.subject | pathologic complete response | en_US |
dc.subject | sTIL | en_US |
dc.subject | sTIL change | en_US |
dc.subject | tumor infiltrating lymphocyte | en_US |
dc.subject | tumor microenvironment | en_US |
dc.subject | breast tumor | en_US |
dc.subject | female | en_US |
dc.subject | human | en_US |
dc.subject | neoadjuvant therapy | en_US |
dc.subject | pathology | en_US |
dc.subject | prognosis | en_US |
dc.subject | tumor associated leukocyte | en_US |
dc.subject | Breast Neoplasms | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Lymphocytes, Tumor-Infiltrating | en_US |
dc.subject | Neoadjuvant Therapy | en_US |
dc.subject | Prognosis | en_US |
dc.title | The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer | en_US |
dc.type | article | en_US |
dc.identifier.issue | 29 | en_US |
dc.identifier.volume | 18 | en_US |
dc.identifier.startpage | 3289 | en_US |
dc.identifier.endpage | 3298 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | Ilgun, A.S., Department of Surgery, Demiroglu Bilim University, Abide-i Hürriyet Cd No:16434387, Turkey; Aktepe, F., Department of Pathology, Sisli Memorial HospitalIstanbul 34384, Turkey; Gonullu, O., Department of Pathology, Sisli Etfal Training & Research HospitalIstanbul 34371, Turkey; Kapucuoglu, N., Department of Pathology, Koc University Medical SchoolIstanbul 34010, Turkey; Yararbas, K., Department of Medical Genetics, Demiroglu Bilim UniversityIstanbul 34349, Turkey; Alco, G., Department of Radiation Oncology, Demiroglu Bilim UniversityIstanbul 34349, Turkey; Ozturk, A., Department of Surgery, Biruni University Medical SchoolIstanbul 34295, Turkey; Elbuken Celebi, F., Department of Radiology, Yeditepe University Medical SchoolIstanbul 34718, Turkey; Erdogan, Z., Physical Therapy & Rehabilitation Center, Medical Park HospitalIstanbul 34732, Turkey; Ordu, C., Department of Medical Oncology, Demiroglu Bilim UniversityIstanbul 34349, Turkey; Unal, C., Department of Medical Oncology, Kartal Lutfi Kirdar Training & Research HospitalIstanbul 34865, Turkey; Duymaz, T., Department of Physical Therapy & Rehabilitation, Bilgi UniversityIstanbul 34060, Turkey; Soybir, G., Department of Surgery, Sisli Memorial HospitalIstanbul 34060, Turkey; Yavuz, E., Tuzlali Pathology LaboratoryIstanbul 34394, Turkey; Tuzlali, S., Tuzl | en_US |
dc.identifier.pmid | 36017739 | en_US |
dc.identifier.scopus | 2-s2.0-85140274865 | en_US |
dc.authorscopusid | 57200631980 | |
dc.authorscopusid | 6602952031 | |
dc.authorscopusid | 57215019648 | |
dc.authorscopusid | 6603125065 | |
dc.authorscopusid | 34468021600 | |
dc.authorscopusid | 35095972600 | |
dc.authorscopusid | 56308186200 |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Scopus İndeksli Yayınlar Koleksiyonu [1747]
Scopus Indexed Publications Collection